GlassScriptPhysician profile
Michele L Ofner
NPI 1821080813
$9,551.50
in general payments reported to CMS, 2019-2025
50 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $792 · 2021: $1,387 · 2022: $1,595 · 2023: $1,344 · 2024: $1,707 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,939 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,939.14 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,245.20 | 2021-2025 | |
| Pfizer INC. | $884.35 | 2021-2025 | |
| Ucb, INC. | $877.34 | 2019-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $517.18 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $503.95 | 2019-2024 | Tysabri, Vumerity, Avonex |
| Kyowa Kirin, INC. | $461.86 | 2019-2024 | Nourianz |
| Sk Life Science, INC. | $429.56 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $411.70 | 2019-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $383.52 | 2019-2023 | |
| Argenx US, INC. | $322.78 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $287.60 | 2023-2025 | |
| Amgen INC. | $284.27 | 2019-2022 | |
| Csl Behring | $275.25 | 2023-2025 | Hizentra |
| Genzyme Corporation | $216.25 | 2019-2023 | |
| C2n Diagnostics, LLC | $216.16 | 2025 | Precivityad2 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Ofner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.